Education
About Us
Working with TipRanks
Follow Us
Verona Pharma Plc (VRNA)
NASDAQ:VRNA
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
>-0.01Last Year’s EPS
-0.11Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: -8.01%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call for Verona Pharma plc reflected a positive sentiment overall, driven by the successful launch and strong sales of O2VERE, significant financial achievements, and robust progress in global regulatory and intellectual property strategies. Despite some financial losses and high expenses, the company's strong cash position and strategic financing provide a solid foundation for continued growth.Company Guidance
In the first quarter of 2025, Verona Pharma plc reported significant progress in the launch of O2VERE, their new COPD treatment, with quarterly revenue surpassing operating expenses excluding noncash charges. O2VERE sales almost doubled compared to the previous quarter, reaching $71.3 million in net product sales. The company recorded a total net revenue of $76.3 million, buoyed by a $5 million milestone from Nuance Pharma. In terms of prescriptions, 25,000 were filled, new patient starts increased by over 25% compared to Q4 2024, and refills accounted for 60% of all expenses. The prescriber base grew by approximately 50%, with around 5,300 prescribers, 60% of whom are tier one healthcare providers. Financially, the company maintained a strong balance sheet with $401.4 million in cash and equivalents and an adjusted net income of $20.5 million, excluding $36.8 million in share-based compensation. Additionally, Verona Pharma amended its financing arrangement, increasing its debt facility to $450 million and repurchasing a $100 million obligation, enhancing financial flexibility.Successful US Launch of O2VERE
O2VERE, the new COPD treatment, nearly doubled its sales from Q4 2024 to Q1 2025, reaching $71.3 million in net product sales. Prescriptions increased to approximately 25,000 filled during the first quarter, with a 25% growth in new patient starts compared to Q4 2024.
Financial Milestones
For the first time, Verona's quarterly revenue exceeded quarterly operating expenses excluding noncash charges. Adjusted net income for the quarter was $20.5 million, excluding $36.8 million in share-based compensation.
Strong Global Strategy and Regulatory Progress
O2VERE was approved in Macau for the treatment of COPD, marking the first regulatory approval outside the US. Nuance Pharma is expected to report results from its pivotal phase three trial for COPD treatment in China in Q2.
Expansion of Intellectual Property
A new Orange Book listed patent for O2VERE with an expiration date in 2044 was granted, bringing the total to four Orange Book listed patents.
Strong Financial Position
Verona ended Q1 2025 with $401.4 million in cash and equivalents, and amended its strategic financing arrangement for increased financial flexibility and reduced cost of capital.
---
VRNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VRNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 29, 2025 | $68.83 | $73.22 | +6.38% |
| Feb 27, 2025 | $63.52 | $67.12 | +5.67% |
| Nov 04, 2024 | $34.98 | $38.15 | +9.06% |
| Aug 08, 2024 | $19.53 | $21.60 | +10.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Verona Pharma Plc (VRNA) report earnings?
Verona Pharma Plc (VRNA) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Verona Pharma Plc (VRNA) earnings time?
Verona Pharma Plc (VRNA) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VRNA EPS forecast?
VRNA EPS forecast for the fiscal quarter 2025 (Q2) is >-0.01.
---